Declaration of interest
Selective serotonin reuptake inhibitors (SSRIs) and cognitive–behavioural therapy (CBT) are often used concomitantly to treat social anxiety disorder (SAD), but few studies have examined the effect of this combination.
To evaluate whether adding escitalopram to internet-delivered CBT (ICBT) improves clinical outcome and alters brain reactivity and connectivity in SAD.
Double-blind, randomised, placebo-controlled neuroimaging trial of ICBT combined either with escitalopram (n = 24) or placebo (n = 24), including a 15-month clinical follow-up (trial registration: ISRCTN24929928).
Escitalopram+ICBT, relative to placebo+ICBT, resulted in significantly more clinical responders, larger reductions in anticipatory speech state anxiety at post-treatment and larger reductions in social anxiety symptom severity at 15-month follow-up and at a trend-level (P = 0.09) at post-treatment. Right amygdala reactivity to emotional faces also decreased more in the escitalopram+ICBT combination relative to placebo+ICBT, and in treatment responders relative to non-responders.
Adding escitalopram improves the outcome of ICBT for SAD and decreased amygdala reactivity is important for anxiolytic treatment response.
- © The Royal College of Psychiatrists 2016.
Log in using your username and password
Log in through your institution
Purchase Short-Term Access
Pay per Article - You may access this article (and download the PDF version) for 1 day for US$30.00.
Pay per Issue - You may access this issue (from the computer you are currently using) for 365 days for US$90.00.
Pay for Admission - You may access all content in The British Journal of Psychiatry (and download the PDF version) for 1 day for US$45.00.
Regain Access - You can regain access to a recent Pay per Article, Pay per Issue, or Pay for Admission purchase if your access period has not yet expired.